ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,214.08
0.51%
US Tech 100
17,691.60
0.29%
다우존스 지수
39,387.76
0.85%
Bitcoin
62,920.28
-0.21%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 영국
  5. LSE
  6. Okyo Pharma Limited (OKYO)

  7. Okyo Pharma Limited (OKYO) 뉴스

OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited
일자:
정렬 기준:
 검색 관련기사 보기:LSE:OKYO
일자시간출처헤드라인심볼기업
2024/05/0820:00UK RegulatoryOKYO Pharma Announces Participation in May 2024 Investor ConferencesLSE:OKYOOkyo Pharma Limited
2024/04/3020:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)LSE:OKYOOkyo Pharma Limited
2024/04/0908:00UK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
2024/04/0220:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
2024/03/2220:00UK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
2024/03/2120:00UK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
2024/03/2020:00UK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
2024/02/0921:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
2024/02/0921:00UK RegulatoryOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
2024/01/3121:00UK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
2023/05/2216:15UK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
2023/05/2216:00UK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
2023/05/1919:22Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
2023/05/1916:00RNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
2023/05/1515:00UK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
2023/05/1122:27Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
2023/05/1120:00RNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
2023/05/1115:00UK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
2023/05/0321:00UK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
2023/05/0315:00RNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
2023/05/0304:16Alliance NewsAlliance NewsTRADING UPDATES: Knights Group buys St James Law and Baines WilsonLSE:OKYOOkyo Pharma Limited
2023/05/0215:00UK RegulatoryOKYO Pharma Limited First-Patient First-Visit for Phase 2 TrialLSE:OKYOOkyo Pharma Limited
2023/04/2600:19Alliance NewsAlliance NewsTRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facilityLSE:OKYOOkyo Pharma Limited
2023/04/2515:00UK RegulatoryOKYO Pharma Limited Activation of First Clinical Trial Site in the U.SLSE:OKYOOkyo Pharma Limited
2023/04/0515:00UK RegulatoryOKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATIONLSE:OKYOOkyo Pharma Limited
2023/04/0417:08Alliance NewsAlliance NewsOkyo Pharma applies to delist from London Stock Exchange due to costsLSE:OKYOOkyo Pharma Limited
2023/04/0415:00UK RegulatoryOKYO Pharma Limited Notice Of Intention To Delist From The LSELSE:OKYOOkyo Pharma Limited
2023/03/3015:00UK RegulatoryOKYO Pharma Limited Director Acquires SharesLSE:OKYOOkyo Pharma Limited
2023/03/2915:00UK RegulatoryOKYO Pharma Limited Director acquires sharesLSE:OKYOOkyo Pharma Limited
2023/03/2416:00UK RegulatoryOKYO Pharma Limited Director/PDMR ShareholdingLSE:OKYOOkyo Pharma Limited
 검색 관련기사 보기:LSE:OKYO

최근 히스토리

NASDAQ
MSFT
Microsoft
NYSE
CVX
Chevron
AMEX
SPY
SPDR S&P 500
SPI
SP500
S&P 500
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
CCOM
SILVER
SILVER
NYSE
JPM
JP Morgan Chase
NYSE
AXP
American Express
NYSE
VZ
Verizon Communications
USOTC
RHHBY
Roche (QX)
CCOM
US500
US 500
NYSE
KO
Coca Cola
COIN
BTCUSD
Bitcoin
FX
USDJPY
US Dollar vs Yen
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유